| Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma L Vercellino, R Di Blasi, S Kanoun, B Tessoulin, C Rossi, M D'Aveni-Piney, ... Blood advances 4 (22), 5607-5615, 2020 | 343 | 2020 |
| SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma RO Casasnovas, M Meignan, A Berriolo-Riedinger, S Bardet, A Julian, ... Blood, The Journal of the American Society of Hematology 118 (1), 37-43, 2011 | 337 | 2011 |
| An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax E Itti, M Meignan, A Berriolo-Riedinger, A Biggi, AF Cashen, P Véra, ... European journal of nuclear medicine and molecular imaging 40, 1312-1320, 2013 | 279 | 2013 |
| Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma M Sasanelli, M Meignan, C Haioun, A Berriolo-Riedinger, ... European journal of nuclear medicine and molecular imaging 41, 2017-2022, 2014 | 240 | 2014 |
| In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic … L Berthet, A Cochet, S Kanoun, A Berriolo-Riedinger, O Humbert, ... Journal of Nuclear Medicine 54 (8), 1244-1250, 2013 | 220 | 2013 |
| Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High–Tumor Burden Follicular Lymphoma Treated With … J Dupuis, A Berriolo-Riedinger, A Julian, P Brice, C Tychyj-Pinel, H Tilly, ... Journal of clinical oncology 30 (35), 4317-4322, 2012 | 214 | 2012 |
| [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy A Berriolo-Riedinger, C Touzery, JM Riedinger, M Toubeau, B Coudert, ... European journal of nuclear medicine and molecular imaging 34, 1915-1924, 2007 | 204 | 2007 |
| PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study RO Casasnovas, R Bouabdallah, P Brice, J Lazarovici, H Ghesquieres, ... The lancet oncology 20 (2), 202-215, 2019 | 195 | 2019 |
| Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma S Kanoun, C Rossi, A Berriolo-Riedinger, I Dygai-Cochet, A Cochet, ... European journal of nuclear medicine and molecular imaging 41, 1735-1743, 2014 | 182 | 2014 |
| Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies J Trotman, S Luminari, S Boussetta, A Versari, J Dupuis, C Tychyj, ... The Lancet Haematology 1 (1), e17-e27, 2014 | 178 | 2014 |
| Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant … B Coudert, JY Pierga, MA Mouret-Reynier, K Kerrou, JM Ferrero, T Petit, ... The Lancet Oncology 15 (13), 1493-1502, 2014 | 157 | 2014 |
| Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma MH Delfau-Larue, A van Der Gucht, J Dupuis, JP Jais, I Nel, ... Blood advances 2 (7), 807-816, 2018 | 133 | 2018 |
| Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F] FDG PET to predict survival in Hodgkin lymphoma S Kanoun, I Tal, A Berriolo-Riedinger, C Rossi, JM Riedinger, ... PloS one 10 (10), e0140830, 2015 | 122 | 2015 |
| Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes O Humbert, A Berriolo-Riedinger, JM Riedinger, B Coudert, L Arnould, ... Annals of oncology 23 (10), 2572-2577, 2012 | 113 | 2012 |
| Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network. P Blanc-Durand, S Jégou, S Kanoun, A Berriolo-Riedinger, C Bodet-Milin, ... European Journal of Nuclear Medicine and Molecular Imaging 48, 1362-1370, 2021 | 107 | 2021 |
| FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study RO Casasnovas, L Ysebaert, C Thieblemont, E Bachy, P Feugier, ... Blood, The Journal of the American Society of Hematology 130 (11), 1315-1326, 2017 | 106 | 2017 |
| Phase II study of a radiotherapy total dose increase in hypoxic lesions identified by 18F-misonidazole PET/CT in patients with non–small cell lung carcinoma (RTEP5 study) P Vera, S Thureau, P Chaumet-Riffaud, R Modzelewski, P Bohn, ... Journal of Nuclear Medicine 58 (7), 1045-1053, 2017 | 93 | 2017 |
| Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients C Rossi, S Kanoun, A Berriolo-Riedinger, I Dygai-Cochet, O Humbert, ... Journal of Nuclear Medicine 55 (4), 569-573, 2014 | 93 | 2014 |
| 18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations A Cochet, I Dygai-Cochet, JM Riedinger, O Humbert, A Berriolo-Riedinger, ... European journal of nuclear medicine and molecular imaging 41, 428-437, 2014 | 92 | 2014 |
| Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer A Cochet, G Quilichini, I Dygai-Cochet, C Touzery, M Toubeau, ... Breast cancer research and treatment 130, 845-854, 2011 | 80 | 2011 |
